The Significance of Urinary Nuclear Matrix Protein ( NMP22 ) Measurement in Patients with transitional Cell Carcinoma of the Bladder.
- Author:
Seok Heun JANG
1
;
Hak Ryong CHOI
;
Bong Suk SHIM
;
Sung Won KWON
Author Information
1. Department of Urology, Pundang Jesaeng General Hospital, Sungnam, Korea.
- Publication Type:Original Article
- Keywords:
Bladder cancer;
NMP22
- MeSH:
Carcinoma, Renal Cell;
Carcinoma, Transitional Cell*;
Enzyme-Linked Immunosorbent Assay;
Healthy Volunteers;
Humans;
Immunoassay;
Instillation, Drug;
Nuclear Matrix*;
Prostatic Neoplasms;
Urinary Bladder Neoplasms;
Urinary Bladder*;
Urinary Tract Infections
- From:Journal of the Korean Cancer Association
1998;30(6):1227-1230
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The objective of this study was to evaluate an immunoassay for urinary nuclear matrix protein (NMP22) as an indicator for transitional cell carcinoma of the bladder. MATERIALS AND METHODS: Three groups of subjects attended the trial of NMP22. First group was 27 patients with transitional cell carcinoma of the bladder, second group was 24 patients with other urinary cancer consisted of prostate cancer and renal cell carcinoma, and third group was 24 healthy volunteers. NMP22 was determined using a commercial test kit, which is based on an enzyme-linked immunosorbent assay. RESULTS: In normal healthy volunteers and other urinary cancer group median NMP22 levels were 2.24 and 3.27 U/ml, respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma of the bladder were 54.30 U/ml. It was significantly greater than other two groups. Median NMP22 levels according to the tumor stage and the tumor grade did not show the significant difference statistically. CONCLUSIONS: Urinary NMP22 is a useful marker that is more specific for bladder cancer thsn for other urinary cancer. Further tests are required to clarify the influence of other spe- cific conditions, such as urinary tract infection, and intravesical drug instillation or procedure.
